Search Results

A PHASE 3 STUDY OF FIXED DOSE COMBINATIONS OF FIANLIMAB AND CEMIPLIMAB VERSUS RELATLIMAB AND NIVOLUMAB IN PARTICIPANTS WITH UNRESECTABLE OR METASTATIC MELANOMA 

A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab

Nadia Ashai, MD, is a fellowship-trained, double-board-certified medical oncologist and hematologist at Maryland Oncology Hematology. She earned her medical degree from the University of Maryland School of Medicine, followed by residency training at the University of Maryland Medical Center. She then completed a fellowship in oncology at the Albert Einstein College of Medicine, Montefiore Medical…

A Prospective, Open-Label, Phase IIb/III Study to Evaluate the Risk of TLS and Optimization of the Initiation of Venetoclax in Combination with Obinutuzumab or Acalabrutinib With Different Ramp-Up Periods in Previously Untreated Subjects with CLL (M24-287)